Current Report Filing (8-k)
13 Marzo 2023 - 5:02PM
Edgar (US Regulatory)
0001726822
false
0001726822
2023-03-13
2023-03-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): March 13, 2023
SOUL
BIOTECHNOLOGY CORPORATION
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
|
000-56213
|
|
82-3155323 |
(State
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
36
Fourth Ave. N, Saskatchewan, Canada |
|
S3N
2V7 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(516)
544-2812
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act: None
Securities
registered pursuant to Section 12(g) of the Act:
Title
of Each Class |
|
Name
of Each Exchange On Which Registered |
Common
Stock, $0.001 par value per share |
|
N/A |
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
March 13, 2023, the sole existing director and officer resigned immediately. Accordingly, David Lazar, serving as a director and an officer,
ceased to be the President, Chief Executive Officer, Chief Financial Officer, and as a Member of the Board of Directors of the Company.
Also on March 13, 2023, Rachel Martinuik consented to the new CEO, CFO, Treasurer, and a Member of the Board of Directors of the Company
and Nichol Martinuik consented to act as the new President, Secretary, and a Member of the Board of Directors of the Company.
Rachel
Martinuik, 47, CEO and Chair of the board of MySpray, has been part of MySpray from inception. In her previous role as Chief Operating
Officer, her responsibilities included the oversight of MySpray’s resources and oversees budgetary expenditures. A large part of
her role was to build relationships with members of the supply chain, production labs, fulfillment, and logistic teams that all operate
for MySpray remotely across Canada. Outside of MySpray, Rachel was appointed by the honorable Brad Wall to a board position for Saskatchewan
Opportunities Corporation (SOCO), where she served three terms, from 2015-2021. SOCO operates under the registered business name of Innovation
Place a Saskatchewan Crown Corporation. Innovation Place owns and operates technology parks adjacent to the province’s universities
in Saskatoon and Regina, which provides a home for 3,800 tech jobs across 150 different companies in well over 1 million square feet
of managed indoor space. In 2018 Rachel earned the ICD.D designation from the Institute of Corporate Directors. Rachel is a graduate
from the University of Regina with a Bachelor of Human Justice. Her education in board management and social justice provides the awareness
to keep the company mindful of the personal, corporate, and social responsibility we occupy.
Nichol
Martinuik, 47, President & Founder of MySpray, has been in health sciences, traditional medicine, and the natural health industry
since 1997, gaining clinical experience in pain management, disease prevention, and therapeutic health solutions. He is a seasoned doctor
of natural medicine (homeopathy), registered massage therapist, and natural health researcher. Nichol is the President and Founder of
MySpray Therapeutics Inc., and HMTC - Homeopathic Medical & Therapy Clinic, and is registered with the Natural Health Practitioners
of Canada and the Saskatchewan Association of Doctors of Natural Medicine.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
March
13, 2023
SOUL
BIOTECHNOLOGY CORPORATION |
|
|
|
|
By: |
/s/
Rachel Martinuik |
|
Name: |
Rachel
Martinuik |
|
Title:
|
CEO |
|
Grafico Azioni Adorbs (CE) (USOTC:ADOB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Adorbs (CE) (USOTC:ADOB)
Storico
Da Dic 2023 a Dic 2024
Notizie in Tempo Reale relative a Adorbs Inc (CE) (OTCMarkets): 0 articoli recenti
Più Soul Biotechnology Corp Articoli Notizie